Literature DB >> 7888547

Plasma levels of tumor necrosis factor alpha in patients with Mediterranean spotted fever: clinical and analytical correlations.

J Oristrell1, M J Amengual, B Font-Creus, A Casanovas, F Segura-Porta.   

Abstract

Twenty consecutive patients with serologically confirmed Mediterranean spotted fever were analyzed for determination of plasma levels of tumor necrosis factor alpha (TNF-alpha) by means of an ELISA. Increased levels of TNF-alpha in plasma were found during the acute phase of the disease (52.3 +/- 49.8 pg/mL) compared to levels in the convalescent phase (9.0 +/- 9.3 pg/mL; P < .001) or in healthy controls (6.5 +/- 3.2 pg/mL; P < .001). Plasma TNF-alpha levels were significantly higher in patients with severe Mediterranean spotted fever. Levels of TNF-alpha correlated significantly with serum levels of C-reactive protein and triglycerides and inversely with serum levels of sodium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888547     DOI: 10.1093/clinids/19.6.1141

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

Review 1.  Host, pathogen and treatment-related prognostic factors in rickettsioses.

Authors:  E Botelho-Nevers; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-26       Impact factor: 3.267

2.  Plasma interleukin-6 levels in Mediterranean spotted fever.

Authors:  J Oristrell; M Sampere; M J Amengual; B Font; F Segura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-22       Impact factor: 3.267

3.  Release of soluble tumor necrosis factor receptors in Mediterranean spotted fever rickettsiosis.

Authors:  W V Kern; J Oristrell; F Segura-Porta; P Kern
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

4.  Modifications of general parameters of immune activation in the sera of Sicilian patients with Boutonneuse fever.

Authors:  S Mansueto; G Vitale; C Mocciaro; G Gambino; P Colletti; P Mansueto; A Spinelli; M Affronti; N Chifari; F Arcoleo; S Milano; E Cillari
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.